Xenon Pharmaceuticals Inc’s filing revealed that its Director GANNON STEVEN unloaded Company’s shares for reported $91.0 on Jun 05 ’25. In the deal valued at $30.48 per share,3 shares were sold. As a result of this transaction, GANNON STEVEN now holds 7,141 shares worth roughly $0.23 million.
Then, MORTIMER IAN sold 22,468 shares, generating $903,214 in total proceeds. Upon selling the shares at $40.20, the PRESIDENT & CEO now owns 31,302 shares.
Before that, MORTIMER IAN sold 16,315 shares. Xenon Pharmaceuticals Inc shares valued at $660,806 were divested by the PRESIDENT & CEO at a price of $40.50 per share. As a result of the transaction, MORTIMER IAN now holds 31,302 shares, worth roughly $1.0 million.
Chardan Capital Markets initiated its Xenon Pharmaceuticals Inc [XENE] rating to a Buy in a research note published on May 07, 2025; the price target was $55. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. H.C. Wainwright started covering the stock on October 01, 2024. It rated XENE as “a Buy”.
Price Performance Review of XENE
On Monday, Xenon Pharmaceuticals Inc [NASDAQ:XENE] saw its stock fall -2.26% to $32.02. Over the last five days, the stock has gained 1.81%. Xenon Pharmaceuticals Inc shares have fallen nearly -18.32% since the year began. Nevertheless, the stocks have fallen -16.53% over the past one year. While a 52-week high of $46.00 was reached on 01/02/25, a 52-week low of $26.74 was recorded on 04/09/25.
Levels Of Support And Resistance For XENE Stock
The 24-hour chart illustrates a support level at 31.39, which if violated will result in even more drops to 30.77. On the upside, there is a resistance level at 32.76. A further resistance level may holdings at 33.51.
The most recent change occurred on January 04, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $62 price target.
